GeoVax Labs (GOVX) 10-Q 3 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 03, 2018
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	832,489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		151,736,810
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
ASSETS
Cash and cash equivalents	$ 571,154	$ 312,727
Grant funds and other receivables	5,000	59,758
Prepaid expenses and other current assets	226,170	75,589
Total current assets	802,324	448,074
Property and equipment, net	26,171	31,151
Deposits	11,010	11,010
Total assets	839,505	490,235
Current liabilities:
Accounts payable	54,039	77,581
Accrued expenses (Note 6)	864,358	733,711
Current portion of note payable	1,042
Total current liabilities	919,439	811,292
Note payable, net of current portion	48,958
Total liabilities	968,397	811,292
Commitments (Note 8)
Stockholders’ equity (deficiency):
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 141,736,810 and 106,736,810 at March 31, 2018 and December 31, 2017	141,737	106,737
Additional paid-in capital	36,219,889	35,589,911
Accumulated deficit	(38,538,603)	(37,916,790)
Total stockholders’ equity (deficiency)	(128,892)	(321,057)
Total liabilities and stockholders’ equity (deficiency)	839,505	490,235
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	76,095	76,095
Series C Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	842,990	842,990
Series D Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	539,000	980,000
Series E Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	$ 590,000

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	141,736,810	106,736,810
Common stock, shares outstanding (in shares)	141,736,810	106,736,810
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	100	100
Preferred stock, shares outstanding (in shares)	100	100
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	2,570	2,570
Preferred stock, shares outstanding (in shares)	2,570	2,570
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	550	1,000
Preferred stock, shares outstanding (in shares)	550	1,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	600	0
Preferred stock, shares outstanding (in shares)	600	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Grant and collaboration revenues	$ 221,299	$ 295,735
Operating expenses:
Research and development	486,994	551,795
General and administrative	357,228	292,667
Total operating expenses	844,222	844,462
Loss from operations	(622,923)	(548,727)
Other income (expense):
Interest income	1,318	386
Interest expense	(208)
Total other income (expense)	1,110	386
Net loss	$ (621,813)	$ (548,341)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average shares outstanding (in shares)	124,170,143	55,350,974

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (621,813)	$ (548,341)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,980	6,898
Stock-based compensation expense	52,549	14,580
Changes in assets and liabilities:
Grant funds and other receivables	54,758	6,560
Prepaid expenses and other current assets	20,848	10,151
Accounts payable and accrued expenses	107,105	178,054
Total adjustments	240,240	216,243
Net cash used in operating activities	(381,573)	(332,098)
Cash flows from investing activities:
Purchase of property and equipment		(4,350)
Net cash used in investing activities		(4,350)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	590,000
Net proceeds from sale of common stock		49,167
Proceeds from issuance of note payable	50,000
Net cash provided in financing activities	640,000	49,167
Net increase (decrease) in cash and cash equivalents	258,427	(287,281)
Cash and cash equivalents at beginning of period	312,727	454,030
Cash and cash equivalents at end of period	$ 571,154	$ 166,749

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Convertible preferred stock (in shares)	450
Conversion of stock, shares issued (in shares)	30,000,000

Note 1 - Description of Busines

Note 1 - Description of Business	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying condensed consolidated financial statements at March 31, 2018 three March 31, 2018 2017 not 10 December 31, 2017. not Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations into the third 2018. not may not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2017 no 10 In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. five 2014 09 January 1, 2018; no In May 2017, 2017 09, Scope of Modification Accounting 2017 09 718, 2017 09 1 2 718 2017 09 January 1, 2018; no There have been no three March 31, 2018, 10 December 31, 2017,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 222.9 91.7 March 31, 2018 2017,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2018 December 31, 2017: March 31, 2018 December 31, 2017 Laboratory equipment $ 530,306 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 674,596 Accumulated depreciation and amortization (648,425 ) (643,445 ) Property and equipment, net $ 26,171 $ 31,151

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2018 December 31, 2017: March 31, 2018 December 31, 2017 Accrued management salaries $ 623,289 $ 532,615 Accrued directors’ fees 214,819 182,620 Other accrued expenses 26,250 18,476 Total accrued expenses $ 864,358 $ 733,711

Note 7 - Note Payable

Note 7 - Note Payable	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	7. On February 28, 2018, five $50,000. 5%, second 0 2018, $10,417 2019, $12,500 2020, 2021 2022, $2,083 2023. five 178,571 9 three March 31, 2018 $208.

Note 8 - Commitments

Note 8 - Commitments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. We lease approximately 8,400 December 31, 2018. March 31, 2018, $117,409 2018. may March 31, 2018, not

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Series B Convertible Preferred Stock As of March 31, 2018, 100 may $0.35 285,714 three March 31, 2018, no Series C Convertible Preferred Stock As of March 31, 2018, 2,570 may $0.015 171,349,733 three March 31, 2018, no Series D Convertible Preferred Stock As of March 31, 2018, 550 may $0.015 36,666,666 three March 31, 2018, 450 30,000,000 Series E Convertible Preferred Stock In March 2018, 600 $1,000 $590,000. Each share of Series E Preferred Stock is entitled to a liquidation preference equal to the initial purchase price, has no not $0.08 may, We assessed the Series E Preferred Stock under ASC Topic 480, Distinguishing Liabilities from Equity 480” 815, Derivatives and Hedging 815” 470, Debt 470” 815 not 815. three March 31, 2018, no Common Stock Transactions As discussed above, during the three March 31, 2018, 30,000,000 450 During the three March 31, 2018, 5,000,000 Stock Options The following table presents a summary of our stock option transactions during the three March 31, 2018: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 7,024,275 $ 0.29 Granted -- -- Exercised -- -- Forfeited or expired (68,334 ) 0.06 Outstanding at March 31, 2018 6,955,941 $ 0.29 Exercisable at March 31, 2018 1,960,284 $ 0.90 Stock Purchase Warrants On February 28, 2018, 7, five 178,571 $0.042 no March 31, 2018. Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $23,978 $14,580 three March 31, 2018 2017, March 31, 2018, $194,302 2.4 Additionally, during the three March 31, 2018 $28,571 March 31, 2018, $171,429 2018.

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Because of our historically significant net operating losses, we have no 382

Note 11 - Grants and Collaborat

Note 11 - Grants and Collaboration Revenue	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Government Grants and Contracts [Text Block]	11. We receive ongoing payments pursuant to grants and contracts from the National Institute of Allergy and Infectious Diseases (NIAID) in support of our vaccine research and development efforts. We record revenue associated with government grants and contracts as the reimbursable costs are incurred. During the three March 31, 2018 2017, $216,299 $295,735, March 31, 2018, $265,396 During the first 2018, $5,000

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	12. In April 2018, Construction and efficacy testing of novel recombinant vaccine designs for eliciting both broadly neutralizing antibodies and T cells against Lassa virus $299,820 April 9, 2018 March 31, 2019. During April 2018, 10,000,000 150

Note 5 - Property and Equipme19

Note 5 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2018 December 31, 2017 Laboratory equipment $ 530,306 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 674,596 Accumulated depreciation and amortization (648,425 ) (643,445 ) Property and equipment, net $ 26,171 $ 31,151

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2018 December 31, 2017 Accrued management salaries $ 623,289 $ 532,615 Accrued directors’ fees 214,819 182,620 Other accrued expenses 26,250 18,476 Total accrued expenses $ 864,358 $ 733,711

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 7,024,275 $ 0.29 Granted -- -- Exercised -- -- Forfeited or expired (68,334 ) 0.06 Outstanding at March 31, 2018 6,955,941 $ 0.29 Exercisable at March 31, 2018 1,960,284 $ 0.90

Note 4 - Basic and Diluted Lo22

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares shares in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	222.9	91.7

Note 5 - Property and Equipme23

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 674,596	$ 674,596
Accumulated depreciation and amortization	(648,425)	(643,445)
Property and equipment, net	26,171	31,151
Laboratory Equipment [Member]
Property and equipment, gross	530,306	530,306
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Accrued management salaries	$ 623,289	$ 532,615
Accrued directors’ fees	214,819	182,620
Other accrued expenses	26,250	18,476
Total accrued expenses	$ 864,358	$ 733,711

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - USD ($)	Feb. 28, 2018	Mar. 31, 2018	Mar. 31, 2017
Proceeds from Notes Payable, Total		$ 50,000
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	178,571
Interest Expense, Total		208
Common Stock Purchase Warrants [Member]
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	178,571
Senior Notes [Member]
Debt Instrument, Term	5 years
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	$ 0
Long-term Debt, Maturities, Repayments of Principal in Year Two	10,417
Long-term Debt, Maturities, Repayments of Principal in Year Three	12,500
Long-term Debt, Maturities, Repayments of Principal in Year Four	12,500
Long-term Debt, Maturities, Repayments of Principal in Year Five	12,500
Long-term Debt, Maturities, Repayments of Principal after Year Five	$ 2,083
Interest Expense, Total		$ 208

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	Mar. 31, 2018USD ($)ft²
Area of Real Estate Property | ft²	8,400
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | $	$ 117,409

Note 9 - Stockholders' Equity27

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2018	Mar. 31, 2017	Feb. 28, 2018	Dec. 31, 2017
Conversion of Stock, Shares Converted		450
Conversion of Stock, Shares Issued		30,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01			$ 0.01
Stock Issued During Period, Shares, Issued for Services		5,000,000
Warrants and Rights Outstanding, Term				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				178,571
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001		$ 0.042	$ 0.001
Class of Warrant or Right, Outstanding	0	0
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 194,302	$ 194,302
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 146 days
Common Stock Issued For Services [Member]
Allocated Share-based Compensation Expense, Total		$ 28,571
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 171,429	171,429
2006 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense, Total		$ 23,978	$ 14,580
Conversion of Series D Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted		450
Stock Issued During Period, Shares, New Issues		30,000,000
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	100	100			100
Convertible Preferred Stock, Conversion Price1	$ 0.35	$ 0.35
Convertible Preferred Stock, Total Conversion Shares	285,714	285,714
Conversion of Stock, Shares Converted		0
Preferred Stock, Par or Stated Value Per Share	$ 1,000	$ 1,000			$ 1,000
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	2,570	2,570			2,570
Convertible Preferred Stock, Conversion Price1	$ 0.015	$ 0.015
Convertible Preferred Stock, Total Conversion Shares	171,349,733	171,349,733
Conversion of Stock, Shares Converted		0
Preferred Stock, Par or Stated Value Per Share	$ 1,000	$ 1,000			$ 1,000
Series D Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	550	550			1,000
Convertible Preferred Stock, Conversion Price1	$ 0.015	$ 0.015
Convertible Preferred Stock, Total Conversion Shares	36,666,666	36,666,666
Conversion of Stock, Shares Converted		450
Conversion of Stock, Shares Issued		30,000,000
Preferred Stock, Par or Stated Value Per Share	$ 1,000	$ 1,000			$ 1,000
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance	600	600			0
Convertible Preferred Stock, Conversion Price1	$ 0.08	$ 0.08
Conversion of Stock, Shares Converted	600
Preferred Stock, Par or Stated Value Per Share	$ 1,000	$ 1,000			$ 1,000
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost	$ 590,000

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Activity of Stock Option Plan (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Outstanding, options (in shares) | shares	7,024,275
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.29
Granted, options (in shares) | shares
Granted, weighted average exercise price, options (in dollars per share) | $ / shares
Exercised, options (in shares) | shares
Exercised , weighted average exercise price, options (in dollars per share) | $ / shares
Forfeited or expired, options (in shares) | shares	(68,334)
Forfeited or expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.06
Outstanding, options (in shares) | shares	6,955,941
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.29
Exercisable, options (in shares) | shares	1,960,284
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.90

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Income Tax Expense (Benefit), Total	$ 0

Note 11 - Grants and Collabor30

Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue from Contract with Customer, Including Assessed Tax	$ 221,299	$ 295,735
Government Contract [Member]
Revenue from Contract with Customer, Including Assessed Tax	5,000
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	216,299	$ 295,735
Unused Grant Funds	$ 265,396

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2019
Conversion of Stock, Shares Converted		450
Conversion of Series D Preferred Stock Into Common Stock [Member]
Stock Issued During Period, Shares, New Issues		30,000,000
Conversion of Stock, Shares Converted		450
Conversion of Series D Preferred Stock Into Common Stock [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues	10,000,000
Conversion of Stock, Shares Converted	150
Scenario, Forecast [Member]
Proceeds from Fast Track I/II Small Business Innovative Research Grant				$ 299,820